23 January 2026 : Clinical Research
Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status
Mehmet Salim Demir
ABCDEFG 1*, Gözde Ağdaş BCFG 1
DOI: 10.12659/MSM.951548
Med Sci Monit 2026; 32:e951548
Table 4 Prognostic nutritional and inflammatory indices according to neoadjuvant chemotherapy protocols.
| Variables | ddAC-THP (n: 72) | TCHP (n: 40) | P value |
|---|---|---|---|
| CONUT Score | 2.17±1.02 | 2.13±0.94 | 0.832 |
| Naples Prognostic Score (NPS) | 2.25±0.93 | 2.82±0.67 | 0.009* |
| Glasgow Prognostic Score (GPS) | 0.18±0.39 | 0.08±0.27 | 0.128 |
| CRP-to-Albumin Ratio (CAR) | 1.53±1.17 | 1.03±0.77 | 0.014* |
| Neutrophil-to-Lymphocyte Ratio (NLR) | 2.99±1.14 | 3.06±1.01 | 0.761 |
| Lymphocyte-to-Monocyte Ratio (LMR) | 3.29±1.88 | 3.03±1.32 | 0.436 |
| Prognostic Nutritional Index (PNI) | 49.70±4.79 | 50.14±4.11 | 0.626 |
| * ddAC-THP – dose-dense adriamycin/cyclophosphamide followed by paclitaxel-trastuzumab-pertuzumab; TCHP – docetaxel-carboplatin-trastuzumab-pertuzumab; CONUT – controlling nutritional status; CRP – C-reactive protein; SD – standard deviation. | |||